Companies › Shanghai Kechow Pharma
4 active drug programs in 10 registered trials: 5 Phase 2, 3 Phase 3, 1 Phase 4, 1 Phase 1; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vemurafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 3 | Colorectal Cancer Metastatic | Dec 2026 |
| tunlametinib MEK1/2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Colorectal Cancer Metastatic; Melanoma; Melanoma Advanced; Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation … | Dec 2026 |
| HL-085 | – | Phase 2 | Neurofibromatosis 1 | Oct 2028 |
| HL-003 | – | Phase 1 | Healthy Subjects | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06867393 | HL-003 | Phase 1 | Healthy Subjects | Other | Aug 2025 |
| NCT06008119 | tunlametinib | Phase 3 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT06008119 | Vemurafenib | Phase 3 | Colorectal Cancer Metastatic | Oncology | Dec 2026 |
| NCT06970353 | tunlametinib | Phase 2 | Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation | Oncology | Dec 2026 |
| NCT06970353 | tunlametinib | Phase 2 | Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation | Oncology | Dec 2026 |
| NCT06008106 | tunlametinib | Phase 3 | Melanoma | Oncology | Sep 2027 |
| NCT07170293 | tunlametinib | Phase 2 | Solid Cancers | Oncology | Sep 2027 |
| NCT07445022 | tunlametinib | Phase 4 | Melanoma Advanced | Oncology | Sep 2028 |
| NCT05331105 | HL-085 | Phase 2 | Neurofibromatosis 1 | Oncology | Oct 2028 |
| NCT07750067 | tunlametinib | Phase 2 | Melanoma Metastatic | Oncology | Jul 2030 |
Pierre Fabre Medicament SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Fore Biotherapeutics Day One Biopharmaceuticals Immuneering
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.